Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 2 SENS-111 dosage regimens (100mg and 200mg) administered orally for 4 days in patients suffering from acute unilateral vestibulopathy.

COMMERCIAL CLINICAL TRIAL